SCHEMBL3363186

SCHEMBL3363186

CC(C)NC(=O)c1ccc(CO)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
LMNA P02545 2/20 0.65
CYP1A2 P05177 1/20 0.65
ALOX15 P16050 1/20 0.65
CYP2C19 P33261 1/20 0.65
PTGS2 P35354 1/20 0.65
MLYCD O95822 1/20 0.56
ACACB O00763 1/20 0.54
ADRB2 P07550 1/20 0.53
ADRB1 P08588 1/20 0.53
ADRB3 P13945 1/20 0.53
EPHX2 P34913 1/20 0.50
POLB P06746 1/20 0.49
TAS1R3 Q7RTX0 2/20 0.49
TAS1R1 Q7RTX1 2/20 0.49
NAMPT P43490 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8590217 0.85 MLYCD (0.70) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL13753439 0.85 ALDH1A1 (0.49) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL14380335 0.85 TAS1R3 (0.67) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL2643888 0.83 ALDH1A1 (0.63) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL20300383 0.83 ALDH1A1 (0.63) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL23513432 0.83 PTGS2 (0.63) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL2643885 0.83 ALDH1A1 (0.63) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL28212563 0.83 ALDH1A1 (0.63) ALDH1A1LMNACYP1A2ALOX15CYP2C19
SCHEMBL21502000 0.81 TAS1R3 (0.67) ALDH1A1LMNACYP1A2ALOX15CYP2C19
Hydrochloric Acid SCHEMBL6442966 0.81 ALDH1A1 (0.61) ALDH1A1LMNACYP1A2ALOX15CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-09-16 US disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-7576117-B1 Cyclic amine CCR3 antagonist TEIJIN LIMITED (JP) 2009-08-18 US disclosed
US-20080161324-A1 Compositions and methods for treatment of viral diseases EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) 2008-07-03 US disclosed
WO-2008033466-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PRE. LTD. (SG) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234378-A1 ALKYLSULFONAMIDE-SUBSTITUTED TRIAZOLES AS MATRIX METALLOPROTEASE INHIBITORS MMP3, MMP11, MMP13 ALDH1A1 1417/4885LMNA 1757/4885CYP1A2 254/4885
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A ALDH1A1 2240/4885LMNA 692/4885CYP1A2 588/4885
US-20080161324-A1 Compositions and methods for treatment of viral diseases HAVCR2, EIF2AK2, RNASE1 ALDH1A1 785/4885LMNA 624/4885CYP1A2 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.